![]() Company demonstrates that the CoPrimer platform technology can be used to identify the presence of SARS-CoV-2 in human saliva samples without first requiring costly and time-consuming RNA extraction, and plans development projects to incorporate extraction-free products in upcoming offerings.Company receives increased patent protection from the United States Patent and Trademark Office for the novel CoPrimer™ technology used in the Company's molecular diagnostic tests.The test uses CoPrimer™ probes and primers developed by Co-Diagnostics with high degrees of sensitivity and specificity Company announced that its partner Clinical Reference Lab has begun selling its CRL Rapid Response™ COVID-19 test directly to consumers, which uses a simple saliva collection device that can be self-administered at home, work or any other setting.Indian CDSCO approval for SARS-CoV-2 2-gene multiplex test expected to be granted soon.CE markings received for both Co-Diagnostics "ABC" and SARS-CoV-2 2-gene tests both tests are designed for use in saliva and other respiratory tract samples like nasal swabs, and sputum.Company completes design work and verification for influenza A, influenza B, and COVID-19 ("ABC") multiplex panel and began distributing on a Research Use Only basis to laboratories in the first week of October.Cash, cash equivalents and marketable securities were $27.3 million as of September 30, 2020, an increase of $26.4 million over.Continues to show strong gross margins of 73% on quarterly sales.Stockholders' equity increased to $52.7 million compared to $1.7 million at the beginning of the year.Quarterly net gain from investment in CoSara increased to $748,000 from $250,000 in Q2.Additionally, CoSara Diagnostics, the Company's India joint venture, also continues COVID-19 sales and reports $3.0 million of revenue in Q3, nearly a 3-fold increase over Q2.Year-to-date net income of $29.7 million and $1.07 per diluted common share.Quarterly net income of $15.7 million and net income per diluted common share of $0.53.Company continues COVID-19 test sales and reports $21.8 million of revenue in Q3.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |